Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)

ConclusionOur results suggest that bevacizumab improves clinical outcome in patients with a high NLR but may be detrimental in those with a high SII.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research